Contact Person : Nilufer Donmez; Last Date for the submission of abstract : Not Available ; Description : Antibody-drug conjugates (ADCs) in late-stage clinical development have shown encouraging therapeutic effects against both solid tumors and hematological malignancies. Significant progress has been made through optimization of parameters.